Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Gastrointestinal Stromal Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Chronic-Phase 6Leukemia 6Blast Crisis 5Sarcoma 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Accelerated Phase 3Carcinoma, Ovarian Epithelial 3Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Meningioma 2Melanoma 2Leukemia, Biphenotypic, Acute 2Fibrosarcoma 2Central Nervous System Neoplasms 2Burkitt Lymphoma 2Breast Neoplasms 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Seminoma 1Sarcoma, Synovial 1

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Congenital Bone Marrow Failure Syndromes × Imatinib Mesylate × Clear all
NCT06090669 2026-06-03

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
75 enrolled
Classical hematology

Congenital Bone Marrow Failure Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡